Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs. The ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Shares in Novo Nordisk fell as much as 3.5 per cent on Monday after detailed trial data on its experimental obesity drug ...

Novo Nordisk has decided to terminate its partnership with Hims & Hers Health concerning the sale of the weight loss drug ...

According to Novo Nordisk, the decision comes after Hims & Hers allegedly failed to comply with laws prohibiting mass sales ...

NHS to monitor the mass rollout that will see around 220,000 people with the "greatest need" receive the weight loss jabs.

Securities lowered its rating on Equifax (NYSE:EFX) stock to Neutral from Buy and trimmed the price target to $285 from $300, following what analysts described as an underwhelming investor day.